HOME >> MEDICINE >> NEWS
Evidence Shows Drug-Psychotherapy Combo Effective For Chronic Depression

WASHINGTON, D.C. -- A new combination of drug treatment and psychotherapy is much more effective than either medication or therapy alone for treating chronic depression, according to preliminary results presented Tuesday, May 18, at the annual meeting of the American Psychiatric Association.

The combination treatment, involving the drug nefazodone and a form of psychotherapy developed specifically to treat chronic depression, also produced the highest response and remission rates for any reported study of chronic depression.

The findings come from the Serzone Chronic Depression Study, the first major study of medication alone, psychotherapy alone, and the combination of both in patients with chronic depression. Nefazodone, prescribed under the brand name Serzone, is used to treat depression and is effective for reducing relapse. The research is funded by Bristol-Myers Squibb Company, makers of Serzone.

Results from the acute phase - the first 12 weeks - of the 80-week study of 681 patients depressed for at least two years shows that a combination of nefazodone and psychotherapy produces an 85 percent response rate. The drug alone leads to a 55 percent rate of response, similar to a 52 percent response rate for psychotherapy.

Nefazodone, alone or in combination therapy, was also associated with improvement in patients much sooner than psychotherapy. The drug also provided significant early and ongoing improvement in insomnia, which is common in chronically depressed patients.

"The extremely large difference in response rates after 12 weeks is truly astonishing," said lead researcher Martin B. Keller, M.D. "This study should put to rest the widespread belief that chronic depression is resistant to drug treatments and psychotherapy." Keller is professor and chairman of the Department of Psychiatry and Human
'"/>

Contact: Scott Turner
Scott_Turner@Brown.edu
401-863-1862
Brown University
18-May-1999


Page: 1 2 3

Related medicine news :

1. Evidence indicates cancer patients unable to intentionally postpone death for significant events
2. Not guilty! Evidence exonerates 328, but many still falsely imprisoned
3. Evidence for shaken baby syndrome is uncertain
4. Evidence suggests that the brain can switch to automatic pilot during learning
5. Evidence that memories are consolidated during sleep
6. Evidence that neurons prune only twigs to rewire themselves
7. Evidence supports two types of heart failure
8. Evidence for warts treatments is weak
9. Evidence does not support psychological treatments for epilepsy
10. Evidence of PSA screening efficacy lacking
11. DDW Studies Present Evidence That Thalomid (Thalidomide) Is Active In Treating Crohns Disease

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... ... at Monmouth, was one of the first doctors in the area to perform ... new approach have been impressive: faster recovery, decreased immediate and long-term pain, and ...
(Date:8/31/2015)... ... ... Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and approved as an ... from Don Bosco Prep in 1990 and was Class Salutatorian. He earned Varsity letters ... senior year. He was inducted into the National Honor Society as a sophomore, was ...
(Date:8/31/2015)... ... 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors can ... that contains a mathematical formula for modifying an image. The LUT changes every pixel's color ... LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or newer. ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet the ... costs? , In a commentary for The American Journal of Managed Care ... “clinical efficacy,” which would bind parties together in agreements to intervene at the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of diseases of the central nervous system ... submission has passed review by the US Food and ... 1 clinical trial in patients with metastatic colon cancer ... 31 December 2015. Bionomics, CEO & Managing ...
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
Cached News: